Resistance Training, Detraining, and Retraining Study 2024 (TraDeRe2024)

NCT06573086 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-04-06

No results posted yet for this study

Summary

The goals of our research project are to identify factors explaining inter-individual variation in responses to resistance training (RT) and the baseline determinants underlying an individual's sensitivity to respond to RT. Moreover, investigators aim to assess whether a responsiveness to RT predicts responsiveness to endurance training (ET). Thus, investigators aim to gain a deeper understanding of exercise adaptation processes. The main questions investigators aim to answer are:

* Can the physiological responses of one RT intervention be extrapolated to a subsequent RT intervention?
* If so, what are the mechanisms underlying differing skeletal muscle growth responses in low, and high responders of skeletal muscle hypertrophy?
* If so, do the low responders of skeletal muscle growth respond more favourably when the amount of RT is increased?
* Are the high, moderate, and low responders of RT also the highest, moderate, and lowest responders to ET?

To examine these main research questions, high (n=30), low (n=30), and moderate (n=30) responders of skeletal muscle growth in response to RT (intervention I, NCT05874986) are reallocated into a subsequent 12-week RT intervention (intervention II) after a detraining period. A subgroup of these participants (n=10) will engage in a 6-week control period before starting the second RT period. Additionally, after intervention II, participants will participate in an ET intervention, lasting 6 weeks.

In this intervention II, reallocated participants will be:

* Resistance training with supervision for 12 weeks
* Consuming deuterium oxide for the assessment of muscle protein synthesis
* Consuming D3-3-methylhistidine for the assessment of acute muscle protein breakdown
* Consuming D3-creatine for the examination of whole-body skeletal muscle mass
* Providing a spot urine sample six (6) times, and urine collection for 24 hours performed twice
* Providing saliva samples (30-32 in total) for the assessment of body water enrichment of deuterium
* Providing a muscle biopsy four or five (4-5) times during the study
* Providing a blood sample fourteen (14) times during the study
* Assessed for body composition and body volume four or five times (4-5) during the study
* Participating in muscle size, maximal dynamic strength and TMS measurements four or five (4-5) times during the study
* Asked to answer questionnaires related to e.g. stress, physical activity, sleep, perceived exertion, and diet
* Participating in recovery measurements before and after the second-to-last and the last RT bout, and once in the days between these RT bouts, consisting of six (6) body volume measurements and six (6) maximal voluntary isometric contraction (kg) tests using horizontal leg press for the assessment of neuromuscular recovery
* Participating in an acute resistance exercise (RE) after the 12-week RT intervention.

Furthermore, in the ET intervention, participants will be:

* Participating in a familiarization session and resting electrocardiograph measurements before the intervention
* Participating in endurance testing consisting of body composition, movement economy, and incremental RAMP testing before and after ET intervention
* Endurance training with supervision for 6 weeks, three times a week.

Conditions

  • Hypertrophy
  • Exercise Training
  • Skeletal Muscle Atrophy
  • Healthy

Interventions

OTHER

Resistance Training

12-week resistance training

Sponsors & Collaborators

  • Academy of Finland

    collaborator OTHER
  • University of Jyvaskyla

    lead OTHER

Principal Investigators

  • Juha P Ahtiainen, Assoc.Prof. · University of Jyväskylä, Faculty of Sport and Health Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-19
Primary Completion
2025-06-15
Completion
2025-06-15

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573086 on ClinicalTrials.gov